MK-677 · Ghrelin Receptor Agonist · Protocol Guide
Ibutamoren (MK-677): The Honest Oral GH Secretagogue Guide
Ibutamoren is the only oral GH secretagogue available. It works. It also produces water retention, raises fasting glucose, and is on the WADA Prohibited List. This guide is direct about the trade-offs.
FDA Status
Off-Label, 503A Compounded
Pharmacy
Optimal Balance Pharmacy (503A licensed)
Medical Service
RxPepsDirect, physician-supervised + glucose monitoring
Access
33 U.S. States
Our promise: Ibutamoren is the only oral option in this category. The water retention is real. The fasting glucose elevation is real. The WADA ban is real. We do not understate any of them.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed May 18, 2026.Section 01
What Ibutamoren Actually Is
Ibutamoren is the only oral compound in the GH-axis category. It was developed by Merck in the 1990s as an oral alternative to injectable GH and growth hormone secretagogues. Phase II and Phase III trials documented durable GH and IGF-1 elevation, body composition improvements, and bone density gains. Merck did not pursue final FDA approval, primarily because the commercial case for off-label use in healthy adults was unclear.
What separates ibutamoren from injectable GH secretagogues: oral once-daily dosing, longer-lasting GH elevation rather than pulsatile, and a side-effect profile that includes water retention, increased appetite, and fasting glucose elevation. The trade-offs are real and worth understanding before starting.
Once daily
Oral capsule. The only oral GH secretagogue in clinical use.
24 hours
GH and IGF-1 elevation duration per dose
20+%
IGF-1 elevation typical at standard dosing in clinical trials
Section 02
Who It Is Actually For
| Profile | Goal | Fit |
|---|---|---|
| Age-related GH decline, prefers oral | Convenience over injectable GH secretagogues | Strong Fit |
| Recovery focus, sleep improvement priority | Deep sleep enhancement, recovery acceleration | Strong Fit |
| Post-injury / surgery, sarcopenia | Lean mass support during recovery | Adjunct Use |
| Prediabetes, diabetes, insulin resistance | Ibutamoren raises fasting glucose | Physician Decision Only |
| Competitive athletes in WADA-tested sport | WADA prohibited as GH secretagogue | Contraindicated |
| Active cancer or significant cancer history | GH-axis elevation contraindicated | Physician Decision Only |
Profile
Goal
Fit
Profile
Goal
Fit
Profile
Goal
Fit
Profile
Goal
Fit
Profile
Goal
Fit
Profile
Goal
Fit
Section 03
How It Works
Ibutamoren binds the growth hormone secretagogue receptor (GHSR-1a), the same receptor that endogenous ghrelin activates. Activation stimulates GH release from the anterior pituitary in a sustained, near-continuous pattern. This differs from CJC / Ipamorelin, which preserves pulsatile release. The continuous GH elevation is part of what produces ibutamoren's larger water retention signal and the higher fasting glucose response.
Section 04
Realistic Expectations
Appetite, Sleep, Water Retention
The earliest signals: increased appetite (ghrelin receptor mechanism), improved sleep depth, and mild water retention. Some patients gain 3 to 5 pounds in the first week that is entirely intracellular water.
IGF-1 Elevation Window
Lab-confirmable IGF-1 elevation. RxPepsDirect physicians typically order a follow-up panel here to confirm response.
Body Composition Shift
Visible body composition changes appear. Sleep quality continues to improve. Some patients notice joint stiffness or mild carpal tunnel symptoms from the water retention.
Steady-State Protocol
Most clinically meaningful changes accumulate over 3 to 6 months. Glucose monitoring should continue through the protocol.
Section 05
Dosing Protocol
| Dose | Use Case | Side Effect Profile | Evidence Basis |
|---|---|---|---|
| 12.5 mg per day (RxPepsDirect starting dose) | First-time users, mild GH support | Mild | Clinical Practice |
| 25 mg per day (standard) | Documented effective dose in Merck Phase III trials | Moderate | Phase III RCT |
| 50 mg per day (high) | Maximum studied dose in trials | Marked | Higher water retention, glucose elevation, no proportional benefit |
Dose
Use Case
Side Effect Profile
Evidence Basis
Dose
Use Case
Side Effect Profile
Evidence Basis
Dose
Use Case
Side Effect Profile
Evidence Basis
Oral capsule, taken once daily before bed to align the GH elevation with the natural nocturnal release window. Long half-life (~24 hours) means steady-state builds over 1 to 2 weeks.
Section 06
Glucose Monitoring Is Not Optional
Ibutamoren elevates fasting glucose in many users. The Nass et al. 2008 trial in older adults documented measurable HbA1c increases. The mechanism is sustained GH elevation reducing insulin sensitivity.
Fasting Glucose + HbA1c + Fasting Insulin
FG under 100 mg/dL, HbA1c under 5.7%
Establishes whether you are a safe candidate. Values in prediabetic range are a relative contraindication.
Fasting Glucose Recheck
No more than 10 mg/dL above baseline
Early signal of insulin sensitivity drift. RxPepsDirect physicians may reduce dose or stop if drift is significant.
HbA1c + Fasting Insulin Recheck
HbA1c under 5.7% maintained
The 90-day window is where sustained glucose effects emerge. Decision point on continued use.
IGF-1
Age-adjusted upper-normal quartile
Confirms ibutamoren is producing the intended GH-axis effect. Drawn at baseline and week 6.
Section 07
Ready to Take
1
Capsule per day, before bed
503A
Compounding pharmacy (Optimal Balance)
Q6 weeks
IGF-1 and glucose check-in
Section 08
Stacking
Pairs Well With
BPC-157 / TB-500
Tissue repair via different mechanisms. Useful for injury recovery alongside GH-axis support.
Resistance training and protein intake
The GH and IGF-1 elevation only translates to body composition gains with appropriate stimulus and substrate.
Consistent sleep schedule
Ibutamoren's effect is most pronounced in patients who already prioritize sleep architecture.
Metformin (with physician oversight)
Counteracts the insulin-sensitivity drift. Common in clinical use for patients with metabolic risk factors.
Approach With Caution
Injectable GH or HGH
Combining produces supraphysiologic GH levels with diminishing benefit and increasing side effects.
Active cancer or recent history
GH-axis elevation contraindicated. Oncologist clearance required.
Diabetic retinopathy
IGF-1 elevation can accelerate progression.
Competitive sport under WADA
Prohibited as GH secretagogue. Sanctions apply regardless of prescription.
Section 09
Pricing
Who You Pay, and What For
Pharmacy: Medication
$1.65 per capsule and up. Compounded and shipped by Optimal Balance Pharmacy, a 503A licensed compounding pharmacy.
Medical Service: Physician Consultation
$39 medical visit fee. Intake consultation including metabolic screening, protocol design, glucose monitoring oversight, and follow-up. Billed by RxPepsDirect.
Section 10
Legal Access (and WADA)
503A Licensed Pharmacy
Optimal Balance Pharmacy
Physician Prescription Required
Compounded medication, Rx only
Off-Label, Legal Practice
Not FDA-approved but legally prescribable
WADA Prohibited (S2)
GH secretagogue, banned in competitive sport
Section 11
Community Q&A
How is this different from Sermorelin?
Different mechanism. Sermorelin is an injectable GHRH analog with pulsatile GH release. Ibutamoren is an oral ghrelin receptor agonist with sustained GH release. Sermorelin is cleaner physiologically. Ibutamoren is more convenient (oral) and produces a larger GH and IGF-1 effect at the cost of water retention and glucose impact.
Will I be hungry all the time?
Ghrelin is the hunger hormone. Activating its receptor increases appetite. Most patients notice a meaningful uptick in hunger especially in the evening. If you are using ibutamoren for body composition while in a deficit, this is a real obstacle to manage.
Do I have to cycle?
Long-term data is limited. Most clinical use involves 3 to 6 month courses with breaks. Continuous indefinite use is not the documented pattern. Glucose drift is a key reason to take periodic breaks.
What if my fasting glucose creeps up?
Your RxPepsDirect physician will review. Options include dose reduction, adding metformin if clinically appropriate, or stopping. The protocol only works when the metabolic trade-off stays acceptable.
What if Optimal Balance is out of stock?
Your RxPepsDirect physician will be notified and you will be contacted before any delay impacts your protocol. You only pay the pharmacy when your prescription actually ships.
Section 12
The RxPepsDirect Model
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your ibutamoren capsules under a patient-specific prescription, USP <795> non-sterile compounding standards (oral capsules), and federal 503A oversight.
Medical Service: RxPepsDirect Physicians
A licensed physician reviews your metabolic baseline, screens for CV and cancer contraindications, designs your protocol, monitors glucose and IGF-1, and writes the prescription.
Transparent Safety Communication
The guide flags the water retention, the glucose elevation signal, the WADA prohibition, and the cancer / diabetes contraindications. We do not hide limitations.
Legal Access in 33 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a physician prescription.
References
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008. PMID: 19017906
- Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011. PMID: 20828837
- Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998. PMID: 9467564
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed RxPepsDirect prescriber.
GHRH analog (GRF 1-29)
Sermorelin protocol guide: pharmacology, dosing, IGF-1 monitoring, and the non-responder reality
The only GHRH analog still Category 1 compoundable. Daily injection, 6 to 12 month protocol, 30 to 40 percent non-responder rate, and IGF-1 the biomarker that decides the answer.
Growth hormone stack
CJC-1295 / Ipamorelin protocol guide: dosing, units-to-mcg, timelines, and the legal pathway
Pulsatility, DAC vs no-DAC, syringe math, the 90-day rule, gray-market purity data, and the 503A pathway. Written for the patient who wants the full picture.
GHRH analog (FDA-approved as Egrifta)
Tesamorelin protocol guide: visceral fat reduction, dosing, and Phase III evidence
The only GHRH analog with Phase III trials and an FDA approval. Visceral fat reduction, the 31 percent non-responder rate, and what reaccumulates when you stop.
Continue reading